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Abstract
Objective. RA can be categorized into late-onset RA (LORA, >6065 years) and young-onset RA (YORA,
3055 years), depending on the patient’s age at disease onset. Since the average age of the population is
continuously increasing, LORA will most probably gain in importance in the future. Despite this growing
importance, LORA has not been the focus of much interest in the past. The aim of this study was to
analyse radiographic damage progression of early disease in LORA compared with YORA patients.
Methods. We included all patients from the Swiss RA registry, Swiss Clinical Quality Management in RA,
with recent-onset arthritis, either RA (disease duration 41 year) or undifferentiated arthritis, as diagnosed
by the data-entering physician. Patients were followed for 5 years. The cut-off between YORA and LORA
was operationally set at 60 years of age. The primary outcome of this study was disease progression and
activity, which was assessed based on the 28-joint DAS (DAS28) and the progression of joint erosions
using a validated scoring system (Ratingen score).
Results. A total of 592 patients with early disease were analysed. The age at disease onset had a
Gaussian distribution, with a single peak at 54 years of age; 366 patients were categorized as YORA
and 226 as LORA at disease onset. DAS28 scores were significantly higher among LORA as compared
with YORA patients (4.8 vs 4.5, P= 0.049). Corticosteroids were used in 68% of LORA patients as a first-
line treatment, compared with 25.4% in YORA patients (2 test: 54.58; P<0.0001). In contrast, DMARDs
were used in 100% of the YORA patients as first-line treatment, compared with 91.2% of the LORA
patients. During follow-up, new glucocorticoids, synthetic DMARDs or biologic DMARDs were initiated
in 32.8%, 61.1% and 14.1% of all YORA patients and 17.5%, 54.6% and 6.6% of LORA patients, re-
spectively (2 test: 7.08, 22.53, 54.4; all P< 0.01). The DAS28 scores decreased in both groups during the
observed time period, and the initial differences in disease activity vanished after 6 months and during the
subsequent follow-up. The Ratingen score was higher in LORA than in YORA patients at inclusion (12.7 vs
5.6, P<0.0001). The rate of radiographic progression at 5 years was similar when comparing LORA and
YORA (3.3 vs 2.6, respectively, P= 0.64). The Ratingen scores at onset and during follow-up over 5 years
did not clearly separate LORA and YORA into two groups, but rather, increased linearly when comparing
the patients in groups per decade from 20 to 92 years of age.
Conclusion. Our results did not show LORA as a separate subgroup of RA with a different prognosis with
regard to radiographic progression.
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Introduction
Young- and late-onset RA (YORA and LORA) have been
described as two separate entities with a different prog-
nosis [1]. YORA usually commences between 30 and 40
years of age, while RA developing after 6065 years of age
is usually called LORA [2, 3]. The incidence of RA has
been described as continuously increasing, reaching a
peak at between 70 and 79 years of age [4].
Consequently, in the ageing populations in many coun-
tries around the world, LORA will most likely gain in im-
portance during the coming decades. Despite this
growing importance, LORA has rarely been investigated
in detail. Previous reports have suggested that the onset
of LORA is more sudden than in younger patients [3].
Disease progression appears to be similar among LORA
and YORA patients [5, 6]. LORA is as damaging [2, 5] or
even more damaging [7] than RA of younger onset. The
literature is divided with respect to joint deformities, which
have been described either as less [8] or more [7] frequent
in LORA. In contrast, the functional classification deter-
mined by the method of Steinbrocker et al. [9] did
not change significantly despite treatment, and com-
plete remission has been called unusual. The use of
DMARDs and low doses of prednisone are the preferred
therapies in LORA patients [6]. It has been suggested that
the use of DMARDs is less frequent than in younger
patients [7].
Predicting future disease progression is particularly im-
portant in early RA, as it may lead to personalized medi-
cine tailored to the individual patient. LORA, in general,
does not present a better prognosis than young-onset
disease [7]. Acute phase reactants, RF and ACPA [10,
11] are important prognostic factors for all RA patients.
Furthermore, HLA-DR4 and high levels of acute phase
reactants at onset have been shown to be associated
with poor radiographic outcome in LORA patients [2, 8].
Even though its prevalence increases with age, it is un-
clear whether RF is more frequent in LORA patients than
in patients with earlier disease onset: higher [8] and lower
[12] percentages of RF have been described for LORA
patients. Ranganath et al. [13] found that acute phase
reactants were higher in LORA patients. However, differ-
ences in CRP and ESR in elderly and younger RA patients
vanished when these factors were corrected for patient
age.
The aim of this study was to analyse disease activity,
serological factors at disease onset and clinical and radio-
graphic disease progression of LORA patients with the
Swiss Clinical Quality Management in RA (SCQM-RA) co-
hort. We compared early RA patients of late and young
disease onset.
Methods
Study population and design
The SCQM-RA is a population- and hospital-based RA
cohort that has been described in detail elsewhere [14,
15]. The SCQM has obtained Swiss-wide ethics approval
to collect patient data and broad consent to perform clin-
ical research related to its aims. Since this project falls into
the outlined research aims, no particular ethical approval
was needed to perform this analysis on anonymized
patient data. In this study we restricted our analysis to
patients with early RA or undifferentiated arthritis (UA).
The analysis includes data collected between January
1998 and November 2011. Inclusion criteria for the ana-
lysis were a diagnosis of RA or UA by a rheumatologist,
and early disease, defined as <367 days of disease dur-
ation after the first symptoms (as defined by the patient).
Patients treated with corticosteroids, synthetic DMARDs
or biologic DMARDs for >31 days before the first visit
were excluded from the analysis. Other exclusion criteria
were missing 28-joint count at baseline or the absence of
follow-up visits.
Outcome parameters
The primary endpoint was the change of DAS28 scores in
the different patient groups. The DAS28 scores were cal-
culated employing the swollen and tender joint counts,
ESR and/or CRP. If both ESR-DAS and CRP-DAS were
available, the average of both scores was used as previ-
ously described [16].
Secondary endpoints were radiographic changes and
functional disability. Functional disability was assessed
with the HAQ. The radiographic outcome was analysed
on serial radiographs according to the number and size
of bone erosions. Erosions were measured prospectively
using a validated scoring system (Ratingen score),
based on the amount of joint-surface destruction for
each joint. The interobserver agreement and testretest
reliability are high, as published [17]. The pre-diagnostic
radiological progression was calculated by baseline
Ratingen score divided by disease duration (difference
between the first symptoms and symptom duration at
the baseline visit).
Statistical analysis
The baseline disease characteristics of patients in the two
groups were compared using standard descriptive statis-
tics. Continuous variables were compared using a
Student’s t-test, and categorical variables with the 2
test. Curves showing changes in DAS28 and HAQ
scores over time were created using loess smoothing of
the raw data. The effect of LORA/YORA on DAS28 and
HAQ scores was estimated using linear mixed models
with random slope and random intercept and adjusted
for various baseline factors in a univariate fashion.
Slopes of the Ratingen score before and after diagnosis
were compared between groups using the MannWhitney
U-test. All statistical analyses were two-sided at the 0.05
significance level. The analyses were performed using
Excel (version 14.2.2; Microsoft, Redmond, WA, USA),
the GraphPad Prism 5 software (GraphPad Software, La
Jolla, CA, USA) and the lme4 package in R (R Project,
Vienna, Austria).
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Results
Patients
Of the 9627 patients in the database, 1345 had a disease
duration <367 days at baseline, 947 patients were not pre-
treated with any corticosteroid or DMARD for >31 days at
baseline; 756 patients could be classified as having RA or
UA, 609 patients had at least one follow-up in the database
and 592 patients in the database had valid 28-joint counts.
The median follow-up for these 592 patients was 44
months (range 0178), representing 3845 visits.
Age at disease onset
To delineate whether two distinct patient groups may
exist, the numbers of patients were analysed at the time
point of disease onset depending on the patients’ age.
This grouped analysis resembled a Gauss distribution
with a single peak between 50 and 60 years (Fig. 1).
Baseline demographic data
Patients were categorized into two groups: YORA
(n= 366, <60 years of age) and LORA (n= 226, >60
years of age). Analysis of the demographic data demon-
strated that YORA patients were more likely to be female:
76.8% of the YORA patients were female, compared with
70.3% of the LORA patients (P= 0.0131). Follow-up (44.2
vs 55.4 months, P= 0.0002) and disease duration (167.2
vs 183.4 days, P= 0.0002) were both somewhat shorter
among LORA patients. Clinically, no differences were
found for the number of tender and swollen joints in the
two groups. LORA patients displayed higher DAS28 and
Ratingen scores, CRP levels and ESR at disease onset
compared with YORA patients (Table 1). These differ-
ences were no longer visible after correction of ESR for
age.
Treatment strategy
First-line treatment was variable. Comparing the first-line
treatments, corticosteroids were used in 68% of the LORA
patients as compared with 25.4% of the YORA patients
(2 test: 54.58, P< 0.0001; Fig. 2B). In contrast, first-line
DMARDs were used in 100% of the younger patients
compared with 91.2% of the older patient group.
During follow-up, up to nine treatment adjustments
were made per patient. An average of 3.25 treatment ad-
justments (0.70 decisions/year) were made among YORA
patients, compared with 2.73 among LORA patients (0.74
decisions/year; Fig. 2A). With regard to the number of ad-
justments for changing therapy to a new synthetic or bio-
logic DMARD, this decision was made in 61.1 and 14.1%
(synthetic and biologic DMARD, respectively) of all deci-
sions documented among YORA patients and 54.6 and
6.6% in LORA patients (2 test: 7.08 and 22.53, respect-
ively; both P< 0.01).
Glucocorticoids were initiated in 32.8 and 17.5% of
LORA and YORA patients, respectively, during follow-up
(2 test: 54.4, P< 0.0001).
TABLE 1 Patient characteristics
YORA LORA P-value
Number 366 226 —
Age, mean (S.D.), years 44.4 (11.0) 68.5 (6.3) <0.0001
Sex, female/male 281/86 159/77 0.013
Follow-up, mean (S.D.), months 55.4 (39.9) 44.2 (33.3) 0.0002
Disease duration, mean (S.D.), days 183.4 (98.4) 167.2 (94.7) 0.047
SJC at onset, mean (S.D.) 7.4 (6.0) 8.0 (5.9) 0.23
TJC at onset, mean (S.D.) 8.1 (7.1) 7.5 (6.0) 0.31
DAS28 at onset, mean (S.D.) 4.4 (1.6) 4.7 (1.5) 0.0489
RF positive at onset, n (%)a 258 (70.5) 130 (57.5) 0.013
CCP positive at onset, n (%)a 99 (67.8) 52 (55.9) 0.06
ESR at onset, mean (S.D.), mm/h 25.6 (23.5) 32.3 (23.7) 0.001
CRP at onset, mean (S.D.), mg/l 16.5 (9.6) 24.5 (14.6) 0.15
Ratingen score at onset, mean (S.D.) 5.6 (6.9) 12.7 (11.3) <0.0001
TJC: tender joint count; SJC: swollen joint count. LORA: late onset RA: >60 years of age; YORA: young onset RA: <60 years
of age. aCalculated on patients with available data.
FIG. 1 Correlation of age and disease onset
Patients were grouped per decade depending on their age
at disease onset. The upper age level of the analysed
patient group is depicted on the x-axis. Data are pre-
sented as the number of patients per group.
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Clinical and radiographic progression
Disease activity at disease onset, assessed by DAS28
scores, was higher among LORA as compared with
YORA patients. During follow-up, this difference vanished
and no further difference was detected during follow-up
comparing the statistical means of both groups (Fig. 3, left
panel). In parallel, no difference for HAQ scores could be
found during follow-up (Fig. 3, right panel). Adjusting for
time to diagnosis, gender, age, medications and baseline
RF, DAS28, Ratingen, HAQ, ESR or CCP scores, there
were no statistically significant differences in changes in
either DAS28 or HAQ scores over time between YORA
and LORA patients (linear mixed models with random
slope and intercept, each adjusting for one of the above
mentioned factors, P> 0.1).
Radiographic progression was analysed using cumula-
tive probability plots. The estimated pre-diagnostic radio-
graphic progression was higher in LORA patients (Fig. 4A).
However, during follow-up radiographic damage pro-
gressed at similar rates in both groups (Fig. 4B). When
radiographic progression was analysed separately for
low (Ratingen score 024) and high rates of destruction
(Ratingen score> 24) in YORA and LORA patients, ana-
lysis revealed some differences. Of the initial 97.0% of
FIG. 2 Treatment strategy
Individual treatment decisions were analysed for the two patient groups, younger patients in dark, older patients in light
grey. The number of adjustments made at the different subsequent points in time (a maximum of nine decisions were
analysed per patient) are shown per patient group independent of which therapeutic adjustment was made. Treatment
changes are depicted as the total number of adjustments (A) or percentages of patients (BE) for whom a decision was
made. In detail, the total numbers or the percentage of total initial patients is shown who underwent a treatment change
independent of a particular change (A), synthetic DMARD therapy (B), change of corticosteroid regimen (C), TNF
antagonist treatment (D), and non-anti-TNF biologic treatment (E).
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YORA patients with low radiographic progression, 83.1%
stayed in this radiographically low active group and the
average percentage of patients with high radiographic
progression increased from 15.4 to 47.4% of the LORA
patients (2 test for Ratingen scores >24 after 5 years:
63.33, P= 0.0002).
Concomitant diseases
The number of co-morbidities was analysed for the pa-
tients in our cohort (Table 2). At disease onset, no
differences in either the number or kind of concomitant
diseases were observed. However, during follow-up 0.54
concomitant diseases per year on average developed in
LORA patients as compared with 0.32 in YORA patients
(P= 0.0001).
Discussion
In this study we analysed a group of 592 RA patients with
early disease depending on the age of onset. In our study,
older patients showed a slightly higher disease activity
FIG. 4 Radiographic progression
Radiographic progression was analysed employing the Ratingen scores over time: (A) pre-diagnostic and (B) yearly
radiographic progression after diagnosis and initiation of therapy are shown as cumulative probability plots. LORA
patients are depicted in black and younger patients in grey. The pre-diagnostic radiological progression was calculated
using the Ratingen score divided by the time difference between the first symptoms and the first visit. For the progression
during follow-up, the change in Ratingen scores was divided by the time between the different radiographs and yearly
progression under therapy was calculated. (C) Percentage of patients developing a Ratingen score >24 over time.
FIG. 3 DAS28 and HAQ scores over time
Patient groups were analysed separately for YORA (solid lines) and LORA patients (dotted lines). Loess smoothed time
courses of DAS28 (left panel) and HAQ (right panel) are depicted per group over 60 months of follow-up with the 95%
confidence interval as grey shade for each group.
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and more joint erosions at disease onset compared with
younger patients. As the disease duration was shorter
among LORA patients, this may reflect more aggressive
disease rather than a longer, smouldering process before
diagnosis.
The border between LORA and YORA has been defined
differentially in the literature. Some authors define LORA
after the age of 65 [2, 5, 7, 12, 18], while others use the
age of 60 [1, 6, 1921] or even as low as 55 years of age
[13]. The average age of the patients in this study was 53.6
years (S.D. 15.1, median 55). Since the patients were
grouped per decade for the analysis, we chose as the
border between LORA and YORA the age of 60 years.
Parallel calculations were also performed for a cut-off at
55 and 65 years. The results did not differ significantly
using these different age thresholds.
These data raise three major questions:
Is LORA a separate form of RA?
Ferraccioli et al. [5] established the concept of a disease
separated into two entities depending on the prognosis
and age of the patients. They found no difference after
the analysis of demographic, serological, and clinical
data and scintiscan pictures. In our study, the significant
clinical differences of the two groups at baseline were
DAS28 scores, positivity for RF, ESR and Ratingen
scores (Table 1). Looking at these factors in detail, the dif-
ference in ESR vanished if values were corrected for age,
as previously published [22, 23]. When a ratio of the age
and the corresponding ESR level was determined, this ratio
was 0.47 for LORA and 0.57 for YORA. Thus, similar to data
published by Ranganath et al. [13], the impact of higher
ESR levels not only vanished, but was reversed, if ESR
was corrected for the patients’ age. If a value 6.7 mm/h
for ESR (the difference of the average ESR levels found in
the LORA and YORA groups at disease onset) is entered
into the formula for calculating DAS28 values, the DAS28
value increases by 0.09 for DAS28 calculated using four
variables and looses statistical significance [16].
The number of patients with substantial radiographic
damage at baseline differed between the LORA and
YORA patients in our study, increasing linearly with age
(data not shown). Thus a clear separation of LORA from
YORA, according to radiographic progression, as sug-
gested by Fig. 4C, seems artificial.
Are older RA patients treated adequately?
Mavragani et al. [6] described that among Greek RA pa-
tients with LORA, DMARDs and low doses of prednisone
represented mainstream therapy. This was similar in our
cohort: LORA patients were more frequently treated with
corticosteroids and less frequently treated with DMARDs
or biologic DMARDs (Fig. 2).
This leads to two different assumptions: either LORA
patients need more aggressive treatment, because they
have more erosive disease at onset, as demonstrated by
the higher Ratingen scores at baseline in our study, or,
despite more erosions and a less aggressive treatment
of LORA patients, the slope of evolving new erosions is
similar to that of YORA patients. Since highly destructive
disease as defined by a Ratingen score >24 was more
frequent among LORA patients (n= 47) at the end of our
observation period than among younger patients (n= 17)
(Fig. 4C), an equally aggressive treatment for LORA pa-
tients seems advisable.
Are physicians more reluctant to initiate aggressive
therapy in LORA patients because of co-morbidities?
The number of co-morbidities was analysed for the pa-
tients in our cohort (Table 2). Surprisingly, no differences
in either the numbers or kinds of concomitant diseases
were found at disease onset. However, the fact that
1.7 times more concomitant disease developed in LORA
patients per year suggests that the presence of
TABLE 2 Concomitant diseases
YORA, n (%) LORA, n (%) P-value
Concomitant disease at baseline per patient 9.6 9.1 0.91
New concomitant disease developed during
follow-up/patient-year
0.32 0.54 0.0001
Most frequent concomitant diseases at diagnosis and during follow-up
Arterial hypertension 296 (80.9) 184 (81.4) 0.82
Diabetes mellitus II 293 (80.1) 171 (75.7) 0.21
Malignant tumour 294 (80.3) 170 (75.2) 0.14
Chronic cardiac disease 291 (79.5) 170 (75.2) 0.22
Alcohol/drug abuse 295 (80.6) 167 (73.9) 0.06
Chronic obstructive pulmonary disease 291 (79.5) 169 (74.8) 0.18
Cerebrovascular disease 292 (79.8) 168 (73.3) 0.12
Chronic nephropathy 292 (79.8) 168 (74.3) 0.12
Psychological diseases/depression 289 (79.0) 168 (74.3) 0.19
Gastric ulcer 291 (79.5) 165 (73.0) 0.07
Degenerative spondylopathy 287 (78.4) 167 (73.9) 0.03
OA 4 (1.1) 11 (4.9) 0.005
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co-morbidities may well have interfered negatively with
the decisions for new therapeutics in LORA patients.
Conclusion
In summary, in our cohort, first, we found no clinical, sero-
logical or radiographic differences justifying a division of
RA into two entities depending on the patient’s age at
disease onset. Secondly, and potentially more import-
antly, our results suggest that LORA patients, if their co-
morbidities allow it, should be treated as aggressively as
younger RA patients.
Rheumatology key messages
. Division of RA into two entities depending on the
patient’s age cannot be justified.
. Late-onset RA patients should be treated as ag-
gressively as younger RA patients, depending on
their co-morbidities.
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